Search results
The aim of the site is to increase the level of awareness and understanding of genetic testing and genetic counselling among people living with inherited retinal dystrophies, empowering them to make fully informed decisions about their lives, healthcare and family planning.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
Saturday 12 October, 1.00pm - 7.00pm - *Rescheduled from 10 August* Come and join us for our second collaborative in-person event of 2024 with Northern Alliance VIP's when we return to The Bridge Hotel in Newcastle.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
Thursday 19 September, 11.00am - In-person - Please come and join us for a guided tour of the new 'Seeing Differently' exhibition at the MK Gallery.
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
Do you want to win up to £25,000 and feel good about supporting people with inherited progressive sight loss?!
